Gossamer Bio Shares Are Trading Higher After Competitor Aerovate Therapeutics Reported Topline Results From the Phase 2b Portion of IMPAHCT Trial of AV-101 for Pulmonary Arterial Hypertension.
Gossamer Bio Shares Are Trading Higher After Competitor Aerovate Therapeutics Reported Topline Results From the Phase 2b Portion of IMPAHCT Trial of AV-101 for Pulmonary Arterial Hypertension.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.